Short- and Long-Term Treatment of Obsessive-Compulsive Disorder with Fluvoxamine
Annals of Clinical PsychiatryPublished 1 June 1992
Gopinath Mallya, K. Geoffrey White, Christine Waternaux, Sara Quay
Citations41
SJR quartileQ3
SJR score0.39
SNIP0.54
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Analysis of the chane scores on the Yale-Brown Scale for O&D show significantly greater improvement with fluvoxamine than with placebo, but the frequency and rapidity of relapse even after prolonged treatment is a concern.
Abstract
AbstractTwenty-eight patients with DSM-III-R diagnosis of obsessive-comulsive disorders completed a 10-week doutle-blind placebo controlled trial of a serotonergic uptake blocker, fluvoxamine. Six patients (43%) improved more than 35% in the fluvoxamine group, whereas only one (7%) patient improved in the placebo group. Analysis of the chane scores on the Yale-Brown Scale for O&D show significantly greater improvement with fluvoxamine than with placebo (Wilcoxon's test p = 0.025). Twenty-one of these atients then particiated in an open triaf with fluvoxamine for a period of two to twelve months. Twelve patients (57%) showed improvement. Seven of nine patients relapsed within a few days to weeks of discontinuation of fluvoxamine. Fluvoxamine in the open phase is found to be safe, effective, and well tolerated but the frequency and rapidity of relapse even after prolonged treatment is a concern.
Keywords
PsychologyNeuroscience
Archives of General PsychiatryThe Yale-Brown Obsessive Compulsive Scale
7,464 Citations1989Wayne K. Goodman
In a study involving four raters and 40 patients with obsessive-compulsive disorder at various stages of treatment, interrater reliability for the total Yale-Brown Scale score and each of the 10 individual items was excellent, with high degree of internal consistency among all item scores demonstrated with Cronbach's alpha coefficient.
Archives of General PsychiatryLifetime Prevalence of Specific Psychiatric Disorders in Three Sites
2,572 Citations1984Lee N. Robins
Lifetime rates are presented for 15 DSM-III psychiatric diagnoses evaluated in three large household samples on the basis of lay interviewers' use of the Diagnostic Interview Schedule.
Biological PsychiatryObsessive-compulsive disorder and serotonin: Is there a connection?
340 Citations1985Thomas R. Insel, Edward A. Mueller +3 more
It is demonstrated that pharmacological blockade of serotonin reuptake alone is not sufficient for an antiobsessional response.
American Journal of PsychiatryReturn of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder
303 Citations1988Michele T. Pato, Rachel C. Zohar-Kadouch +2 more
Treatment duration before discontinuation of clomipramine was not related to the frequency or severity of obsessive-compulsive or depressive symptom appearance, suggesting that prolonged drug treatment may be warranted for obsessive-Compulsive disorder.
PubMedThe epidemiology of obsessive compulsive disorder.
223 Citations1984Steven A. Rasmussen, Ming T. Tsuang
The application of recently developed diagnostic criteria, psychometric testing, and biologic markers to epidemiologic studies of OCD should provide important new data for increasing the understanding of the pathogenesis of the disorder.
Archives of General PsychiatryControlled Comparisons of Clomipramine and Fluoxetine in the Treatment of Obsessive-Compulsive Disorder
221 Citations1990Teresa A. Pigott
Fluoxetine may represent a viable alternative to clomipramine in the treatment of obsessive-compulsive disorder, although further studies with larger sample sizes are needed.
American Journal of PsychiatryFluvoxamine treatment of obsessive-compulsive disorder
213 Citations1987Teri Perse, John H. Greist +3 more
Fluvoxamine treatment was associated with significant improvement on measures of obsessive-compulsive symptoms, anxiety, and depression, and depressed subjects' improvement on obsessive-Compulsive measures correlated with improvement in symptoms of depression.
PubMedThe efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
187 Citations1993Christopher J. McDougle, W K Goodman +4 more
Journal of Clinical PsychopharmacologyFluoxetine Treatment of Obsessive-Compulsive Disorder
167 Citations1985Samuel M. Turner, Rolf G. Jacob +2 more
The results suggest that fluoxetine affected depressive symptoms but also had an effect on self-reported measures of obsessions and ritualistic behavior, and patients' ability to tolerate the drug.
American Journal of PsychiatryA controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory
163 Citations1990M A Jenike, Steven E. Hyman +7 more
Patients with primary obsessive-compulsive disorder participated in a 10-week, double-blind, placebo-controlled trial of the potent, selective serotonin reuptake inhibitor fluvoxamine, finding it significantly better than placebo on two of three measures of improvement in obsessive- compulsive symptoms.
European Journal of PharmacologyBehavioral aspects of serotonin-dopamine interaction in the monkey
146 Citations1985Søren Korsgaard, Jes Gerlach +1 more
Findings support the suggestion that5-HT inhibits dopamine functions and may imply that 5-HT antagonists could have a beneficial effect against acute extrapyramidal side-effects of neuroleptic treatment.
American Journal of PsychiatrySertraline in obsessive-compulsive disorder: a double-blind comparison with placebo [published erratum appears in Am J Psychiatry 1990 Oct;147(10):1393]
72 Citations1990Michael A. Jenike, Lee Baer +4 more
Preliminary findings suggest that sertraline was ineffective according to four measures of obsessive-compulsive symptoms and the need to explore the role of other neurochemical systems in this disorder.
Pharmacology Biochemistry and BehaviorEfficacy of trazodone as an anti obsessional agent
26 Citations1985Ashoka Jahnavi Prasad
Eight patients with chronic Obsessive-Compulsive Neurosis were subjected to Trazodone, an antidepressant acting on the serotinergic system, and 6 showed significant reduction in the obsessional symptoms which was sustained after a 6-week follow-up.
Palgrave Macmillan UK eBooksA review of the properties of a new specific 5-HT reuptake inhibitor — fluvoxamine maleate
7 Citations1983Jennifer S. Wakelin
This work attempted to confirm this activity in the clinic of a new non-tricyclic compound which, pharmacologically, was characterized as an antidepressant with few side-effects.